Search

Your search keyword '"Hamad, Azzam"' showing total 4 results
Start Over Author "Hamad, Azzam"
4 results on '"Hamad, Azzam"'

2. Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy.

Author

Shakiba, Yasmin, Vorobyev, Pavel O., Mahmoud, Marah, Hamad, Azzam, Kochetkov, Dmitriy V., Yusubalieva, Gaukhar M., Baklaushev, Vladimir P., Chumakov, Peter M., and Lipatova, Anastasia V.

Subjects
VACCINIA, ONCOGENIC viruses, ONCOLYTIC virotherapy, KILLER cells, IMMUNOTHERAPY, BIOENGINEERING, T cells
Abstract

Cancer virotherapy is an alternative therapeutic approach based on the viruses that selectively infect and kill tumor cells. Vaccinia virus (VV) is a member of the Poxviridae, a family of enveloped viruses with a large linear double-stranded DNA genome. The proven safety of the VV strains as well as considerable transgene capacity of the viral genome, make VV an excellent platform for creating recombinant oncolytic viruses for cancer therapy. Furthermore, various genetic modifications can increase tumor selectivity and therapeutic efficacy of VV by arming it with the immune-modulatory genes or proapoptotic molecules, boosting the host immune system, and increasing cross-priming recognition of the tumor cells by T-cells or NK cells. In this review, we summarized the data on bioengineering approaches to develop recombinant VV strains for enhanced cancer immunotherapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

3. Multiomic Profiling Identified EGF Receptor Signaling as a Potential Inhibitor of Type I Interferon Response in Models of Oncolytic Therapy by Vesicular Stomatitis Virus

Author

Nikitina, Anastasia S., primary, Lipatova, Anastasia V., additional, Goncharov, Anton O., additional, Kliuchnikova, Anna A., additional, Pyatnitskiy, Mikhail A., additional, Kuznetsova, Ksenia G., additional, Hamad, Azzam, additional, Vorobyev, Pavel O., additional, Alekseeva, Olga N., additional, Mahmoud, Marah, additional, Shakiba, Yasmin, additional, Anufrieva, Ksenia S., additional, Arapidi, Georgy P., additional, Ivanov, Mark V., additional, Tarasova, Irina A., additional, Gorshkov, Mikhail V., additional, Chumakov, Peter M., additional, and Moshkovskii, Sergei A., additional

Published
2022
Full Text
View/download PDF

4. Recombinant Strains of Oncolytic Vaccinia Virus for Cancer Immunotherapy.

Author

Shakiba Y, Vorobyev PO, Mahmoud M, Hamad A, Kochetkov DV, Yusubalieva GM, Baklaushev VP, Chumakov PM, and Lipatova AV

Subjects
Vaccinia virus genetics, Immunotherapy, Gene Editing, Genome, Viral, Oncolytic Viruses genetics, Neoplasms therapy
Abstract

Cancer virotherapy is an alternative therapeutic approach based on the viruses that selectively infect and kill tumor cells. Vaccinia virus (VV) is a member of the Poxviridae, a family of enveloped viruses with a large linear double-stranded DNA genome. The proven safety of the VV strains as well as considerable transgene capacity of the viral genome, make VV an excellent platform for creating recombinant oncolytic viruses for cancer therapy. Furthermore, various genetic modifications can increase tumor selectivity and therapeutic efficacy of VV by arming it with the immune-modulatory genes or proapoptotic molecules, boosting the host immune system, and increasing cross-priming recognition of the tumor cells by T-cells or NK cells. In this review, we summarized the data on bioengineering approaches to develop recombinant VV strains for enhanced cancer immunotherapy.

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results